Shanghai Mental Health Center
Shanghai, China
NCT Number: NCT06474650
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164 sustained-release tablets 30 mg in healthy subjects.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Shanghai, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single-dose of 30 mg of LPM3770164 sustained release tablet
Other names: LY03015
Time frame: Predose and up to 240 hours postdose
Time frame: Predose and up to 240 hours postdose
Time frame: Predose and up to 240 hours postdose
Time frame: from baseline to day 25
Time frame: Predose and up to 240 hours postdose
Time frame: Predose and up to 240 hours postdose
Luye Pharma Group Ltd.
Industry
A Randomized, Open-label, Two-period, Double-crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06216054
Basal Ganglia Diseases, Brain Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05238701
Basal Ganglia Diseases, Brain Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06667414
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05157074
Basal Ganglia Diseases, Behavior
Baltimore, Maryland, United States
View Trial Details